Arxis, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of innovative therapies for patients suffering from respiratory diseases. The company's primary focus is on addressing significant unmet medical needs in conditions such as chronic obstructive pulmonary disease (COPD) and asthma. Arxis leverages its proprietary technology platform to design and develop novel drug candidates that target specific biological pathways involved in respiratory inflammation and airway remodeling. Its lead product candidate, ARX-101, is an inhaled small molecule being evaluated for its potential to improve lung function and reduce exacerbations in patients with severe respiratory conditions. By utilizing a lung-targeted drug delivery approach, Arxis aims to maximize therapeutic efficacy at the site of disease while minimizing systemic side effects. The company's strategy involves advancing its clinical pipeline through rigorous testing and seeking regulatory approvals to bring life-changing treatments to a global patient population. Arxis is headquartered in the United States and continues to invest in research and development to expand its portfolio of respiratory-focused therapeutics.
How many years of EBITDA are required to pay off the company's net debt, according to the official accounting standard IFRS16. As a market consensus, a value of up to 3 years of leverage is accepted for most companies.
How much the company's debt represents in % in relation to its equity. As a market consensus, a value less than or equal to 1 is accepted, above that leverage can end up hurting the final result at some point.
The current ratio helps investors understand more about a company's ability to cover its short-term debt with its current assets and make apples-to-apples comparisons with its competitors and peers.
The quick ratio measures a company's capacity to pay its current liabilities without needing to sell its inventory or obtain additional financing and is considered a more conservative measure than the current ratio, which includes all current assets as coverage for current liabilities.
The interest coverage ratio is used to measure how well a firm can pay the interest due on outstanding debt and is is calculated by dividing a company's earnings before interest and taxes (EBIT) by its interest expense during a given period. Generally, a higher coverage ratio is better, although the ideal ratio may vary by industry.
...and much more!